· Periodic Report
Q3 revenue KRW 13.4 billion, operating loss KRW 1.3 billion
In Q3, Engenbio sold KRW 13.4 billion worth and lost KRW 1.3 billion from its main business; sales rose 147.5% from a year earlier and 7.9% from the prior quarter.
NGeneBio Co., Ltd. Disclosures
354200 · KOSDAQ · Based on DART filings
Disclosures
7 total · 20 per page
· Shareholder Register Record Date
Record date set for Nov 25 for extraordinary shareholders meeting
The record date for determining shareholders entitled to participate in the extraordinary general meeting was set for November 25, 2026.
· Shareholders' Meeting
EGM called for Dec 21 to elect a director
An extraordinary general meeting will be held on December 21 to elect a director, with a record date of November 25.
· Report on Large ShareholdingsMajor
Sangsangin Savings Bank stake falls from 24.71% to 16.96% on CB price adjustment and collateral changes
Sangsangin Savings Bank reported its stake in the company fell from 24.71% to 16.96%, due to convertible bond price adjustment and collateral disposal right changes.
· Material Event Report
KRW 6.0 billion third-party rights offering, largest shareholder fund to take 6,000,000 shares
It will allot 6,000,000 common shares at KRW 1,000 each to its largest shareholder fund to raise KRW 6.0 billion for operating funds.
· Material Event Report
KRW 2.0 billion third-party rights offering, 2,000,000 shares to largest shareholder fund
The company will issue 2,000,000 new shares at KRW 1,000 each in a KRW 2.0 billion third-party allotment to its largest shareholder fund to repay debt.
· Report on Large Shareholdings
SynergyIB Investment stake falls from 5.26% to 0% after convertible bond repayment
SynergyIB Investment Co.Ltd's stake in NGeneBio Co., Ltd. changed from 5.26% to 0% after repayment of the 4th convertible bonds. The stated purpose was simple investment.
Catch the next disclosure fast
Get app alerts for new disclosures from NGeneBio Co., Ltd..